Business Context and Reporting Period
Immuron Limited, a foreign private issuer based in Australia, filed this Form 6-K for the month of October 2019. The filing serves to disclose a specific public announcement made to the Australian Securities Exchange on October 2, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific funding event rather than comprehensive financial statements.
- Funding Event: US Defense funds provided AU$5.5 million for a new gastro weapon.
Material Changes
The primary material change disclosed is the receipt of AU$5.5 million in funding from US Defense sources. The filing does not provide comparative financial data against prior periods to quantify changes in operational metrics.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the funding for the "New Gastro Weapon." The filing does not contain specific forward-looking guidance, risk factors, contingencies, or details on unusual items beyond the funding announcement itself.
Investor Verification Checklist
- Verify the terms and conditions of the AU$5.5 million funding agreement with US Defense.
- Confirm the specific scope and development stage of the "New Gastro Weapon" project.
- Review the attached Public Notice (Exhibit 99.1) for further details on the funding structure.